Find an Alzheimer's clinical trial

If you are thinking about joining a trial

A listing here is a record that a study was registered. It is not a recommendation, and it does not mean the study is still recruiting or that anyone is eligible. Registry entries go stale.

Talk to the treating doctor first, then contact the study team listed on the official ClinicalTrials.gov record. The NIA's free referral line can help you look: 1-800-438-4380, weekdays, English and Spanish.

Search title, drug, condition or sponsor

Recruiting

Exact registry status

Phase

Intervention class

Study type

Country

Results per page

Clear filters Download all 7,816 as CSV

"Open to new participants" means the registry status is RECRUITING or NOT_YET_RECRUITING — 1,523 of the 7,816 records. That is what the sponsor last told the registry, which can be months out of date.
Location is by country. This pull of the registry records the countries a study runs in, not its individual sites, so we cannot filter by US state or city — and we are not going to guess one. To find the nearest site, open a trial's record below: the official page lists every location with its contact details.

Showing 526–550 of 7,816 matching trials · page 22 of 313, 25 per page.

Sorted by the date the registry record was last updated, newest first. This page never loads all 7,816 rows at once — use the CSV download if you want the whole file.

Registered Alzheimer's clinical trials. Every ID links to its official ClinicalTrials.gov record.
Trial	Phase	Status	Enrolled	Sponsor	Last updated
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001 NCT01760005 Gantenerumab; Solanezumab; Matching Placebo (Gantenerumab); Matchin... Runs in: Argentina; Australia; Brazil; Canada; Colombia; France; G... · 38 sites	PHASE2\|PHASE3 anti-amyloid-antibody	ACTIVE_NOT_RECRUITING	490	Washington University School of Medicine OTHER	2026-07-27
Methodology Issues in a Tailored Light Treatment for Persons With Dementia NCT01816152 High Active intervention; Inactive intervention; Mid Level Active I... Runs in: United States · 2 sites	NA other	COMPLETED	44	Icahn School of Medicine at Mount Sinai OTHER	2026-07-27
Use of Gou-Teng to Treat Patients With Mild Cognitive Impairment NCT04532697 Uncaria Rhynchophylla (Gou-Teng); Placebo Runs in: Hong Kong · 1 site	NA other	COMPLETED	56	Chinese University of Hong Kong OTHER	2026-07-27
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU) NCT05269394 E2814; Lecanemab; Matching Placebo (E2814) Runs in: Argentina; Australia; Brazil; Canada; Colombia; France; G... · 36 sites	PHASE2\|PHASE3 anti-amyloid-antibody	ACTIVE_NOT_RECRUITING	197	Washington University School of Medicine OTHER	2026-07-27
Community-based Brain Health Program to Address Dementia Risk NCT05529706 Brain Health Program Runs in: United States · 1 site	NA other	COMPLETED	86	Posit Science Corporation INDUSTRY	2026-07-27
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation NCT05552157 Remternetug (SC); Matching Placebo (Remternetug) Runs in: Argentina; Australia; Canada; Colombia; France; Germany; ... · 37 sites	PHASE2\|PHASE3 anti-amyloid-antibody	RECRUITING	280	Washington University School of Medicine OTHER	2026-07-27
COMMETS- Combination MCI Metabolic Syndrome NCT06072963 Semaglutide; Intranasal insulin; Semaglutide placebo; Intranasal in... Runs in: Israel · 1 site	PHASE2 GLP-1	RECRUITING	80	Rutgers, The State University of New Jersey OTHER	2026-07-27
DIAN-TU Amyloid Removal Trial (ART) in Dominantly Inherited Alzheimer's Disease NCT06384573 lecanemab Runs in: Australia; United Kingdom; United States · 6 sites	PHASE3 anti-amyloid-antibody	ACTIVE_NOT_RECRUITING	40	Washington University School of Medicine OTHER	2026-07-27
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation NCT06647498 Remternetug; Matching Placebo (Remternetug) Runs in: Argentina; Australia; Canada; Colombia; France; Germany; ... · 37 sites	PHASE2\|PHASE3 anti-amyloid-antibody	RECRUITING	280	Washington University School of Medicine OTHER	2026-07-27
Ozanimod in Patients With Alzheimer's Disease NCT06862960 Ozanimod; Conventional medication Runs in: China · 1 site	PHASE2 other	RECRUITING	40	ChenXiaoChun OTHER	2026-07-27
Enhancing Attention in Elderly Using a Brain-Computer-Interface NCT07441122 transcranial electrical stimulation; Mindfulness Meditation Runs in: United States · 2 sites	NA other	RECRUITING	100	University of Texas at Austin OTHER	2026-07-27
Effect and Safety of Non-invasive Electrical Stimulation in Alzheimer's Disease NCT07694921 Temporal Interference Stimulation Runs in: China · 1 site	NA other	ENROLLING_BY_INVITATION	30	First Affiliated Hospital of Zhejiang University OTHER	2026-07-27
A Study to Test the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Patients With Mild Cognitive Impairment or Mild Alzheimer's Disease (AD) NCT04867616 Placebo; Bepranemab Runs in: Belgium; Canada; France; Germany; Italy; Netherlands; Pol... · 103 sites	PHASE2 anti-tau	COMPLETED	466	UCB Biopharma SRL INDUSTRY	2026-07-24
Investigating Speech Sequencing in Neurotypical Speakers and Persons With Disordered Speech NCT05437159 Learning of non-native phoneme combinations: 6 training sessions; L... Runs in: United States · 3 sites	NA other	COMPLETED	278	Boston University Charles River Campus OTHER	2026-07-24
Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia Psychosis NCT07095465 ACP-204 Runs in: Bulgaria; Czechia; France; Italy; Serbia; United States · 30 sites	PHASE3 other	ENROLLING_BY_INVITATION	126	ACADIA Pharmaceuticals Inc. INDUSTRY	2026-07-24
Michigan Healthy Mom (MI-MOM) Pregnancy Improvement Web Application Trial NCT07213284 MI MOM App Runs in: United States · 8 sites	NA other	RECRUITING	500	Michigan State University OTHER	2026-07-24
An Extension of SKY-0515 in Participants With Huntington's Disease NCT07537075 SKY-0515 Runs in: Australia; New Zealand · 10 sites	PHASE2\|PHASE3 other	ENROLLING_BY_INVITATION	500	Skyhawk Therapeutics, Inc. INDUSTRY	2026-07-24
Impact of Nilotinib on Safety, Biomarkers and Clinical Outcomes in Mild to Moderate Alzheimer's Disease NCT02947893 Placebo Capsule(s) Once a Day by Mouth; Nilotinib Capsule(s) Once a... Runs in: United States · 1 site	PHASE2 other	COMPLETED	37	Georgetown University OTHER	2026-07-23
Testing the Pain Clinical Practice Guideline NCT05858996 Pain-CPG-EIT; Pain-CPG-Education Only Runs in: United States · 11 sites	PHASE2 other	RECRUITING	300	University of Maryland, Baltimore OTHER	2026-07-23
Pragmatic Use of PAIN-Advanced Dementia Scale in Emergency Departments NCT06370572 PAINAD EHR Prompt Runs in: United States · 2 sites	NA other	COMPLETED	2,421	University of Chicago OTHER	2026-07-23
Delirium and Cognitive Impairment Development in Hospitalized Older Adults Under Isolation Conditions NCT07114458 Runs in: Germany · 1 site	NA other	RECRUITING	404	Universitätsklinikum Hamburg-Eppendorf OTHER	2026-07-23
SleepSMART for Veterans With Insomnia and Mild Cognitive Impairment NCT07397182 Cognitive BehavioralTherapy for Insomnia (CBT-I); SleepSMART Runs in: United States · 1 site	NA other	NOT_YET_RECRUITING	150	VA Office of Research and Development OTHER_GOV	2026-07-23
Digital Dementia Registry Bavaria (digiDEM Bayern): a Multicentre, Prospective, Longitudinal Register Study Including People With Mild Cognitive Impairment and Dementia as Well as Their Family Caregivers NCT07721701 Runs in: Germany · 12 sites	NA other	RECRUITING	5,000	University of Erlangen-Nürnberg Medical School OTHER	2026-07-23
An Evaluation of Treatments for Sustained Clinical Response (18 Months) in Symptomatic Alzheimer's Disease NCT07724132 Placebo; Atomoxetine; Metformin 1000 mg Oral Tablet Runs in: United Kingdom · 2 sites	PHASE3 other	RECRUITING	1,200	University College, London OTHER	2026-07-23
To Assess the Efficacy and Safety of Ceftriaxone in Patients With Mild to Moderate Parkinson's Disease Dementia NCT03413384 Ceftriaxone; Placebo Runs in: Taiwan · 6 sites	PHASE2 other	COMPLETED	100	BrainX Corporation INDUSTRY	2026-07-22

This table is wider than a phone screen — swipe it sideways to see the rest.

Where these trials come from

Registry: ClinicalTrials.gov, pulled through their public API (v2)
Trials in the file: 7,816
Source file: trials.csv (3.8 MB, 7816 rows)
Basis: Measured These are registry records as submitted by each study's sponsor.

What could make this misleading

Sponsors enter their own data and do not always keep it current, so "recruiting" can be out of date by months or years. Enrollment figures may be targets rather than actual numbers; the downloaded file says which for each trial. Trials that were never registered do not appear at all, and the intervention class is this project's own grouping, not the registry's.

Always check the official record before acting on anything here. This is a summary, not medical advice.

From the research library

The highest-scoring studies we hold on this subject, each summarised in plain English. Scores are alzhub's usefulness score, not a verdict on the science.

Clinical trials

MINocyclinE to Reduce inflammation and blood-brain barrier leakage in small Vessel diseAse (MINERVA): A phase II, randomized, double-blind, placebo-controlled experimental medicine trial Alzheimer's & dementia : the journal of the Alzheimer's Association, 2024 · score 88/100
Safety and efficacy of crenezumab in cognitively unimpaired carriers of the PSEN1Glu280Ala mutation at risk for autosomal-dominant Alzheimer's disease in Colombia (API ADAD Colombia Trial): a phase 2, randomised, double-blind, placebo-controlled trial The Lancet. Neurology, 2026 · score 86/100
Study of mirtazapine for agitated behaviours in dementia (SYMBAD): a randomised, double-blind, placebo-controlled trial Lancet (London, England), 2021 · score 86/100
Randomized, double-blind study of zervimesine in mild to moderate Alzheimer's disease Journal of Alzheimer's disease : JAD, 2026 · score 86/100
Efficacy assessment of an active tau immunotherapy in Alzheimer's disease patients with amyloid and tau pathology: a post hoc analysis of the "ADAMANT" randomised, placebo-controlled, double-blind, multi-centre, phase 2 clinical trial EBioMedicine, 2024 · score 85/100

All 162 studies on Clinical trials →